跨国药企开门红巨头领跑减重赛道 “王牌”产品成增长胜负手_老虎社区_美港股上老虎

跨国药企开门红巨头领跑减重赛道 “王牌”产品成增长胜负手

21世纪经济报道05-08

2026年第一季度，全球制药巨头的业绩版图再度刷新。　　一边，礼来凭借替尔泊肽的强势爆发点燃增长引擎，诺和诺德用司美格鲁肽四条管线合计突破528亿丹麦克朗全线扩张；另一边，默沙东在K药顶住专利竞争压力的同时开始培育新一代增长点，赛诺菲以Dupixent续写自免领域的统治传奇。　　在多款核心产品的合力带动下，这些跨国药企在2026年强势开局。　　有券商医药行业分析师对21世纪经济报道记者表示，当前...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2633410627?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-08 07:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633410627","market":"hk","top_or_hot":-1,"title":"跨国药企开门红 巨头领跑减重赛道 “王牌”产品成增长胜负手","media":"21世纪经济报道","content":"<div>\n<p>2026年第一季度，全球制药巨头的业绩版图再度刷新。　　一边，礼来凭借替尔泊肽的强势爆发点燃增长引擎，诺和诺德用司美格鲁肽四条管线合计突破528亿丹麦克朗全线扩张；另一边，默沙东在K药顶住专利竞争压力的同时开始培育新一代增长点，赛诺菲以Dupixent续写自免领域的统治传奇。　　在多款核心产品的合力带动下，这些跨国药企在2026年强势开局。　　有券商医药行业分析师对21世纪经济报道记者表示，当前...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202605083730569459.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>跨国药企开门红 巨头领跑减重赛道 “王牌”产品成增长胜负手</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n跨国药企开门红 巨头领跑减重赛道 “王牌”产品成增长胜负手\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-08 07:52 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202605083730569459.html><strong>21世纪经济报道</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2026年第一季度，全球制药巨头的业绩版图再度刷新。　　一边，礼来凭借替尔泊肽的强势爆发点燃增长引擎，诺和诺德用司美格鲁肽四条管线合计突破528亿丹麦克朗全线扩张；另一边，默沙东在K药顶住专利竞争压力的同时开始培育新一代增长点，赛诺菲以Dupixent续写自免领域的统治传奇。　　在多款核心产品的合力带动下，这些跨国药企在2026年强势开局。　　有券商医药行业分析师对21世纪经济报道记者表示，当前...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202605083730569459.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0432979614.USD","symbol_name":"JPM GLOBAL HEALTHCARE \"A\" ACC","start_time":0,"source_url":"http://finance.eastmoney.com/a/202605083730569459.html","article_id":"2633410627","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605083730569459.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2633410627","pubTimestamp":1778197920,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"【跨国药企开门红 巨头领跑减重赛道 “王牌”产品成增长胜负手】有券商医药行业分析师对21世纪经济报道记者表示，当前跨国药企的业绩已高度“超级重磅药化”，手握“王牌”产品足以决定公司的增长、估值乃至战略走向。纵观财报数据，一个清晰的信号也正在浮现：在专利悬崖、政策博弈与市场竞争的多重挑战中，如何深度挖掘并战略性运营核心大单品，已从“增长选择”演变为“生存命题”。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0942090050.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD)  INC","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","MRK":"默沙东","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","LU0861579265.USD":"联博低波幅策略股票基金A","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0234572021.USD":"高盛美国核心股票组合Acc","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","SG9999001176.USD":"United Global Healthcare Acc USD","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4532":"文艺复兴科技持仓","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4534":"瑞士信贷持仓","LU0859254822.USD":"T ROWE PRICE GLOBAL VALUE EQUITY \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU2357627491.SGD":"TRP GLOBAL VALUE EQUITY \"AH\" (SGDHDG) ACC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","BK4516":"特朗普概念","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1069347547.HKD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (HKD) INC","NVO":"诺和诺德","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1917777945.USD":"安联专题基金Cl AT Acc","NVOH":"Novo Nordisk A/S B Shares ADRhedged","SG9999002232.USD":"Allianz Global High Payout USD","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","BK4585":"ETF&股票定投概念","SG9999002224.SGD":"Allianz Global High Payout SGD","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","NVOX":"2倍做多NVO ETF-Defiance","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","SG9999014542.SGD":"United Income Focus Trust Acc SGD","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","SNY":"赛诺菲安万特","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","BK4559":"巴菲特持仓","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","BK4588":"碎股","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BK4550":"红杉资本持仓","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU0058720904.USD":"联博国际健康护理基金A","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","BK4599":"减肥药","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LLY":"礼来","LU0868494708.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","SG9999014559.SGD":"United Income Focus Trust Dis SGD","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","BK4007":"制药","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC"},"translate_title":"Multinational pharmaceutical companies have made a good start, giants lead the weight loss track, and \"ace\" products become the winners of growth","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1.93,"NVOX":0.6,"SNY":1.87,"NVOH":0.6,"NVO":1.94,"MRK":1.89},"content_text":"2026年第一季度，全球制药巨头的业绩版图再度刷新。　　一边，礼来凭借替尔泊肽的强势爆发点燃增长引擎，诺和诺德用司美格鲁肽四条管线合计突破528亿丹麦克朗全线扩张；另一边，默沙东在K药顶住专利竞争压力的同时开始培育新一代增长点，赛诺菲以Dupixent续写自免领域的统治传奇。　　在多款核心产品的合力带动下，这些跨国药企在2026年强势开局。　　有券商医药行业分析师对21世纪经济报道记者表示，当前跨国药企的业绩已高度“超级重磅药化”，手握“王牌”产品足以决定公司的增长、估值乃至战略走向。　　纵观财报数据，一个清晰的信号也正在浮现：在专利悬崖、政策博弈与市场竞争的多重挑战中，如何深度挖掘并战略性运营核心大单品，已从“增长选择”演变为“生存命题”。　　GLP-1“双巨头”高歌猛进　　2026年开年，礼来以一份炸裂的业绩向外界证明，代谢赛道是当下最值得重仓的方向之一。根据财报，礼来2026年一季报实现营收197.99亿美元，同比增长56%；净利润同比暴涨168%至73.96亿美元，每股收益达8.26美元，同比增长179%。　　替尔泊肽撑起礼来接近三分之二的营收：降糖版Mounjaro第一季度收入86.62亿美元，同比大增125%，减重版Zepbound也贡献了41.6亿美元，同比增长80%。　　这意味着，替尔泊肽整体贡献约128亿美元，在礼来期内总收入占比高达64%。值得注意的是，Mounjaro海外市场的销量增长，部分得益于该药物在中国被纳入医保目录。　　代谢赛道的另一侧，诺和诺德的司美格鲁肽同样延续全线增长的态势。根据2026年第一季度财报，期内诺和诺德销售达968.23亿丹麦克朗，以固定汇率计算增长32%。司美格鲁肽合计销售额突破528.88亿丹麦克朗。其中减重版Wegovy注射液收入182.35亿丹麦克朗，降糖版Ozempic收入278.25亿丹麦克朗，减重版口服片剂Wegovy贡献22.56亿丹麦克朗，降糖版口服片剂诺和忻收入45.72亿丹麦克朗。　　四种剂型全面出击，显示出诺和诺德在GLP-1赛道上从注射到口服、从减重到降糖的全场景覆盖能力。　　在代谢赛道“双雄并立”的同时，两大巨头亦开始积极布局下一代产品。　　礼来口服小分子GLP-1受体激动剂Foundayo于4月1日获美国FDA批准上市，成为全球首个口服小分子非肽类GLP-1受体激动剂，公司寄望其能大幅扩大受益人群。　　诺和诺德减重版口服片剂Wegovy处方量同样快速增长，一季度单季处方超过130万张，累计超过200万张。此外，诺和诺德还宣布国家药品监督管理局于3月正式批准依柯胰岛素司美格鲁肽注射液诺和杰在中国的上市申请，该药是全球首个且目前唯一获批的基础胰岛素/GLP-1RA周制剂，计划2026年下半年在中国全球首发。　　前述分析师指出，目前口服GLP-1的竞争已从“诺和诺德单点领先”升级为“礼来追赶+全面对标”的格局。　　“小分子路线在成本和规模化生产上潜力巨大，未来，谁能实现‘高质量+低成本+稳供应’，谁就能掌握市场主动权。”该分析师说。　　除了GLP-1市场的竞争，各家跨国药企也在聚焦各自的“王牌”产品扩展以寻找市场增量。　　默沙东财报显示，2026年第一季度公司销售额达162.9亿美元，超出分析师预期的158.3亿美元，增长主要来源于Keytruda需求强劲及新产品Winrevair和Keytruda皮下注射剂型的贡献。K药以约80亿美元的单季收入实力，继续扮演核心支柱的角色。　　尽管整体业绩超出预期，但默沙东同时也收窄了全年的财务展望，外界普遍关注K药专利到期后公司如何平稳过渡。默沙东并非毫无准备——K药皮下注射剂型已在今年Q1初步展现增长潜力，Winrevair等新药也在逐步接力。　　赛诺菲2026年第一季度交出一份亮眼成绩单，总销售额达105.1亿欧元（约合122.9亿美元），按固定汇率计算增长13.6%，营业利润29.7亿欧元（约34.7亿美元），两者均超市场预期。核心重磅产品度普利尤单抗继续扮演挑大梁的角色，单季销售额达41.7亿欧元，同比增长30.8%，再次突破40亿欧元大关。　　然而在业绩报喜之下，赛诺菲的担忧同样明显。投资者和高管层均已敏锐意识到：Dupixent的专利将于下个十年初到期，而赛诺菲至今尚未拿出一条足以填补这一收入缺口的确定性管线。　　多挑战下突围　　2026年，专利到期的“定时炸弹”对一众巨头而言是个不小的挑战。　　例如，百时美施贵宝在发布2025年四季度财报时，其中一个核心主题便是多款重磅药品正面临专利保护到期的挑战。血癌药物Revlimid和Sprycel的销量持续下滑，且这两款药物分别于2022年和2024年失去专利独占权。未来几年，抗凝药Eliquis和抗癌药Opdivo的专利保护也将陆续到期，而这对组合去年全球销售额总计达245亿美元，占公司总收入的51%。　　此外，价格政策亦在全面收紧。2026年4月，国务院办公厅印发《关于健全药品价格形成机制的若干意见》，从创新药首发价格自评、医保谈判支付标准联动、集采常态化推进、线上线下比价透明等多维度重塑药品定价规则。　　前述分析师认为，面对定价压力、仿制药围猎和资本市场预期持续压低的局面，跨国药企的突围策略正呈现几条明确的路径。　　其一，横向延伸适应症和剂型矩阵，延长产品生命周期。K药和Dupixent都在反复演绎该策略——通过扩大适应症覆盖面和推出皮下注射等新剂型给产品“续命”。　　其二，深挖中国创新资产的BD价值。2026年一季度中国创新药对外授权交易总额突破600亿美元，跨国大药企通过海外BD资产买入、合作开发与股权投资等方式，以小成本撬动高壁垒创新管线，成为“对冲专利悬崖”的主流思路。　　其三，押注高度差异化的前沿赛道并加速资产组合的多极化。诺华Pluvicto筑起核药技术壁垒，阿斯利康牢牢占据ADC和罕见病新药的高地，礼来与诺和诺德在口服小分子GLP-1领域率先落子，均展现出从“大单品依赖”向“多极增长”的主动转型。　　“面对专利、市场和政策的多重挑战，头部药企正寻求突破：一方面，在巩固现有‘药王’地位的同时，积极培育下一代增长引擎；另一方面，将ADC、核药、RNA疗法、基因编辑等前沿技术视为长期战略资产，通过内部研发与外延并购持续加码，以分散单一技术路径的风险。”前述分析师进一步指出。　　“当核心重磅药既是跨国药企手中赖以盈利的王牌，也是迫使其推动战略变革的‘隐形枷锁’时，谁能在守护当下业绩的同时，有魄力在专利悬崖之前完成下一代管线的前瞻性布局，谁才有可能在全球制药格局持续重构的下一个十年中赢得先机。”该分析师强调。（文章来源：21世纪经济报道）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}